HIV
10. Clinically significant active or known history of liver disease. (Hepatitis B and
Hepatitis C)
11. Hemorrhage or bleeding event at NCI-CTCAE v5.0 Grade 3 or higher within 28 days of
first dose.
12. history of or ongoing Von Willebrand disease and/or other past or present bleeding
disorders
13. Increased serum calcium 14. Inability to swallow oral medications 15. Ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks. No
chemotherapy, immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within prior 2 weeks
16. Concomitant systemic or glucocorticoid therapy within 2 weeks 17. Major surgical procedure or significant traumatic injury within 4 weeks prior to first
dose or anticipates need for major surgery while on study
18. Concomitant medicines that are strong CYP3A inhibitors 19. History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of
treatment from these drugs
20. Underlying medical conditions in investigator's opinion to be unfavorable to be a part
of the study
21. Has been administered a live vaccine within 4 weeks (28 days) of initiation of study
treatment. NOTE: injectable seasonal vaccines for influenza and COVID-19 are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.